Buy or sell Ginkgo Bioworks stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
Ginkgo Bioworks Stock
Custom Microbes Design
About Ginkgo Bioworks Stock
Ginkgo Bioworks is a biotech company that designs custom microbes. The company creates custom microbes for three main areas: cultured ingredients, strain improvement, and enzymes. For cultured ingredients, Ginkgo Bioworks creates engineered yeasts to produce ingredients via fermentation for perfumes, foods, cosmetics, etc. For strain improvement, Ginkgo Bioworks engineers in-use organisms to improve efficiency and sustainability. For enzymes, Ginkgo Bioworks aims to discover "better" enzymes for various applications, such as cheesemaking and pharmaceuticals.
Ginkgo Bioworks' platform consists of its Foundries and Codebase. Foundries are Ginkgo Bioworks way to automate organism design and Codebase is Ginkgo Bioworks' library of cell, enzyme and genetic programs that help jumpstart new programs and discoveries.
Ginkgo Bioworks was founded in 2009. The company is based in Boston, Massachusetts.
Investors
Allen & Company
Stripe, Vroom, Ginkgo Bioworks, Joby Aviation, Blend, Convoy, Freenome, Turo, OfferUp, Qumulo
Baillie Gifford
Flipkart, Spotify, Indigo, Ginkgo Bioworks, Tempus, Scopely, Zymergen, Joby Aviation, AUTO1 Group, Carbon
Cascade Investment
Ginkgo Bioworks, Convoy, Delos, Schrodinger, OANDA Corporation
General Atlantic
AppDynamics, Toutiao, Chime, Wish, Avant, Ginkgo Bioworks, Automation Anywhere, Blend, Box, Grove Collaborative
Senator Investment Group
T. Rowe Price
Flipkart, WeWork, Cruise, Airbnb, Rivian, Magic Leap, Caris Life Sciences, Vroom, Ginkgo Bioworks, Deliveroo
Viking Global Investors
Impossible Foods, Moderna Therapeutics, Ginkgo Bioworks, Adaptive Biotechnologies, Druva, Apeel Sciences, Arctic Wolf, Talkdesk, Color, Credit Karma
Y Combinator
Airbnb, Instacart, DoorDash, Stripe, Rappi, Flexport, Ginkgo Bioworks, Coinbase, Convoy, Machine Zone
Funding History
| July 2015 | $53.2M |
|---|---|
| June 2016 | $98.9M |
| October 2017 | $294M |
| September 2019 | $627M |
Management
Chief Executive Officer
Jason Kelly
Co-Founder
Barry Canton
Co-Founder
Austin Che
Co-Founder
Tom Knight
Co-Founder
Reshma Shetty
Press
endpts - Sep, 10 2020
TechCrunch - Aug, 26 2020
finsmes - May, 28 2020
Wall Streets Journal - Apr, 30 2020
PR Newswire - Apr, 15 2020
Forbes - Mar, 20 2020
Forbes - Jan, 21 2020
Yahoo Finance! - Jan, 13 2020
businessinsider - Oct, 9 2019
Forbes - Aug, 5 2019
fiercebiotech - Jun, 12 2019
Wall Streets Journal - May, 21 2019
xconomy - May, 15 2019
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Ginkgo Bioworks or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
